Golden Tongues Cordyceps

Metadata

Regulatory Status

China (People’s Republic)

• TCM Pharmacopoeia: Not listed as an official monograph in the Chinese Pharmacopoeia. However, it is documented in traditional Chinese medical texts as a rare medicinal fungus.
• Traditional Use: Recognized in Chinese folk medicine for gynecological conditions, particularly postpartum hemorrhage and menstrual disorders.
• Classification: Classified as a medicinal fungus of “hot temperature” nature in TCM terminology.

United States

• FDA Status: No GRAS determination. Not marketed as a dietary supplement.
• Drug Development Interest: Balanol has been the subject of pharmaceutical research as a protein kinase C inhibitor, but no approved drugs have resulted.

European Union

• Status: Not authorized as a food or food supplement. Not evaluated by EMA/HMPC.
• Research Interest: Known primarily in European mycological and pharmacological research literature.

Japan

• Status: Not specifically approved. Known in mycological literature but not commercially marketed as a medicinal product.

Conditions & Indications

Primary Indications (Traditional Use / In Vitro Evidence)

• Postpartum hemorrhage (traditional) — The aqueous extract of C. ophioglossoides has been used traditionally in Chinese medicine for the treatment of massive postpartum vaginal bleeding. This represents the most documented traditional clinical application, though no modern clinical trials have validated this use.
• Postmenopausal syndrome (traditional) — In TCM, the species is used as an herbal remedy of “hot temperature” nature for relieving postmenopausal symptoms in women, including hot flashes and menstrual irregularities.
• Antifungal infections (preclinical) — Ophiocordin demonstrates selective antifungal activity against multiple fungal taxonomic groups, though bacteria are not inhibited. This represents a potential application for antifungal drug development.

Secondary Indications (In Vitro / Preclinical)

• Cancer (drug discovery target) — Balanol inhibits protein kinase C (PKC), a key signaling enzyme involved in cancer cell proliferation, angiogenesis, and metastasis. PKC inhibition also has implications for CNS diseases, cardiovascular diseases, diabetes, asthma, and HIV. Cordycepol C demonstrates cytotoxic activity against select cancer cell lines.
• Antioxidant and anti-aging — Extracts demonstrate antioxidant activity in vitro, consistent with the presence of phenolic compounds and tyrosol.
• Estrogenic activity — Estrogenic properties have been reported for extracts, potentially relevant to the traditional gynecological applications.

Emerging/Preclinical Indications

• Protein kinase C-related diseases — Balanol’s potent PKC inhibitory activity positions it as a lead compound for drug development across multiple disease categories including cancer, CNS disorders, cardiovascular disease, diabetes, and inflammatory conditions.
• Antimicrobial drug discovery — Ophiocordin’s unique antifungal mechanism, distinct from existing antifungal drug classes, represents potential for novel antifungal drug development.
• Caspase-dependent apoptosis — Some bioactive compounds from C. ophioglossoides demonstrate caspase-dependent pro-apoptotic activities, relevant to cancer research.

Mechanism of Action

Primary Mechanisms

1. Ophiocordin antifungal activity Ophiocordin (C21H22N2O8, molecular weight 430) was isolated from submerged cultures of C. ophioglossoides grown in glycerol-soybean meal medium at 27 degrees C. The compound inhibits growth of fungi belonging to different taxonomic groups but does not affect bacteria, indicating a fungal-specific mechanism. The antifungal effect is notably antagonized by ammonia ions, nitrate ions, and certain amino acids, suggesting that ophiocordin may interfere with nitrogen metabolism or amino acid transport in susceptible fungi. The precise molecular target remains to be fully elucidated.

2. Balanol protein kinase C inhibition Balanol is a potent, non-selective inhibitor of protein kinase C (PKC) isozymes, binding to the ATP-binding site of the kinase domain. PKC is a family of serine/threonine kinases involved in signal transduction pathways controlling cell growth, differentiation, apoptosis, and immune function. By inhibiting PKC, balanol can suppress cancer cell proliferation, modulate immune responses, and affect vascular smooth muscle tone. The compound has been extensively studied as a pharmacological tool and potential drug lead, with research demonstrating inhibition of cancer cell growth in vitro across multiple cell lines.

3. Cordycepol C cytotoxicity Cordycepol C is a sesquiterpene with direct cytotoxic activity against cancer cell lines. The mechanism involves induction of apoptosis through caspase-dependent pathways, consistent with the broader sesquiterpene pharmacology observed across fungal natural products.

Secondary Mechanisms

• Ophiosetin antimicrobial activity: Ophiosetin, a tetramic acid derivative, contributes to the antimicrobial spectrum of C. ophioglossoides. Tetramic acid derivatives are known to chelate metal ions and disrupt cellular membranes.
• Tyrosol antioxidant activity: Tyrosol, a phenolic compound also found in olive oil, contributes to the antioxidant capacity of extracts through free radical scavenging and metal ion chelation.
• Peptaibiotics: C. ophioglossoides produces peptaibiotics (peptides with alpha-aminoisobutyric acid), which form ion channels in biological membranes and contribute to antimicrobial defense.
• Estrogenic mechanisms: The reported estrogenic activity may involve phytoestrogen-like binding to estrogen receptors, potentially mediated by phenolic metabolites, though the specific compounds responsible have not been identified.

Clinical Evidence Summary

No human clinical trials have been published for Cordyceps ophioglossoides. Evidence derives from traditional use documentation, in vitro studies, and biochemical characterization of isolated compounds.

Key Research Studies

Evidence Limitations

• No human clinical trials exist for any indication.
• Traditional use documentation for postpartum hemorrhage and postmenopausal syndrome is based on ethnobotanical reports rather than controlled clinical observations.
• Most compound characterization studies focus on individual isolated metabolites rather than whole extracts, making it difficult to assess the pharmacology of traditional preparations.
• The species is a truffle parasite (parasitizing Elaphomyces species) and is difficult to cultivate for commercial production, though submerged culture methods have been developed for metabolite production.
• Balanol research is primarily in the context of pharmaceutical drug development rather than traditional herbal medicine applications.
• Cross-study standardization is limited due to variable growth conditions and extraction methods.
• Publication bias toward novel compound isolation over pharmacological validation of traditional use claims.

Safety Profile

General Assessment

Limited formal safety data exist for C. ophioglossoides. The species has a history of traditional use in Chinese medicine for gynecological conditions, suggesting a degree of empirical safety at traditional doses. However, the presence of potent bioactive compounds (balanol as a PKC inhibitor, cordycepol C as a cytotoxic agent) warrants caution, particularly at concentrated or extracted doses.

Contraindications

• Pregnancy and lactation: Despite traditional use for postpartum hemorrhage, this species should be avoided during pregnancy and lactation due to the absence of reproductive safety data. The presence of compounds with estrogenic activity and cytotoxic potential poses theoretical risks.
• Known allergy to Cordyceps species: Cross-reactivity is possible. Discontinue immediately if allergic reactions occur.
• Immunosuppressive therapy: Theoretical interaction with immunosuppressants due to immunomodulatory polysaccharide content. Avoid concomitant use without specialist supervision.

Drug Interactions

No specific drug interactions have been clinically documented. Theoretical interactions include:

• Antifungal medications: Ophiocordin’s antifungal activity could theoretically interact (synergistically or antagonistically) with prescribed antifungal agents.
• Anticoagulants/antiplatelets: Traditional use for postpartum hemorrhage may indicate hemostatic properties; interaction potential with anticoagulants is unclear.
• Cancer chemotherapy: Balanol’s PKC inhibitory activity could theoretically interact with PKC-targeted or kinase-targeted cancer therapies. Severity: Theoretical.

Side Effects

No systematically documented side effects. Based on the traditional use profile and general Cordyceps safety, mild gastrointestinal effects are possible. The presence of potent bioactive metabolites suggests caution with high-dose or concentrated preparations.

Clinical Dosage

Traditional Preparation (TCM)

• Aqueous decoction: No standardized dosing established in modern terms. Traditional preparations involved aqueous extraction of the fruiting body (stroma).
• Traditional application: Used for postpartum hemorrhage and menstrual disorders; specific doses varied by practitioner.

Research Context

• Dosing guidelines for human use cannot be provided due to the absence of human clinical trials.
• Submerged culture production of ophiocordin and balanol is conducted at research scale; these are not formulated as consumer products.
• Any therapeutic use should be considered experimental and conducted only under qualified professional supervision.

General Cordyceps Reference

• Standard Cordyceps species dosing (3-4.5 g/day of dried fruiting body) may serve as a very rough reference, but the unique metabolite profile of C. ophioglossoides makes direct dose extrapolation from other Cordyceps species unreliable.

Sources

• Kneifel H, Konig WA, Loeffler W, Muller R. Ophiocordin, an antifungal antibiotic of Cordyceps ophioglossoides. Arch Microbiol. 1977;113(1-2):121-130
• Koide H, Nagata K, Ando T. Comparison of balanol from Verticillium balanoides and ophiocordin from Cordyceps ophioglossoides. J Antibiot (Tokyo). 1996;49(11):1177-1178
• Alali FQ, Anaya J, Oberlies NH. Ophiosetin, a new tetramic acid derivative from the mycopathogenic fungus Elaphocordyceps ophioglossoides. J Antibiot (Tokyo). 2010;63(1):53-55
• Quandt CA, Kepler RM, Gams W, et al. Phylogenetic-based nomenclatural proposals for Ophiocordycipitaceae (Hypocreales) with new combinations in Tolypocladium. IMA Fungus. 2014;5(1):121-134
• Ng TB, Wang HX. Pharmacological actions of Cordyceps, a prized folk medicine. J Pharm Pharmacol. 2005;57(12):1509-1519
• Zhu JS, Halpern GM, Jones K. The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis: part I. J Altern Complement Med. 1998;4(3):289-303
• Wang N, Wu Y, Bao Y, et al. Gram-level production of balanol through regulatory pathway and medium optimization in herb fungus Tolypocladium ophioglossoides. J Fungi. 2022;8(5):510
• Paterson RRM. Cordyceps — a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry. 2008;69(7):1469-1495
• Yue K, Ye M, Zhou Z, Sun W, Lin X. The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol. 2013;65(4):474-493
• Sung GH, Hywel-Jones NL, Sung JM, Luangsa-ard JJ, Shrestha B, Spatafora JW. Phylogenetic classification of Cordyceps and the clavicipitaceous fungi. Stud Mycol. 2007;57:5-59

Connections

• Compare with Cordyceps (O. sinensis) — the premier traditional Cordyceps species; C. ophioglossoides shares the Cordyceps heritage but has a fundamentally different ecology (truffle parasite rather than insect parasite) and a distinct metabolite profile dominated by ophiocordin and balanol rather than cordycepin
• Compare with Cordyceps militaris — the most commercially cultivated Cordyceps species; C. militaris is cordycepin-focused while C. ophioglossoides is distinguished by its unique antibiotic and kinase inhibitor production
• Compare with Cordyceps cicadae — another entomopathogenic Cordyceps with TCM heritage; both share traditional Chinese medicine lineage but target different clinical applications
• The PKC-inhibitory activity of balanol connects to broader kinase-targeted cancer research, an area where fungal natural products have been particularly productive (compare staurosporine from Streptomyces)
• Reishi shares the dual immunomodulatory approach (polysaccharides for immune activation, terpenoids for anti-inflammatory effects), though C. ophioglossoides has a more limited evidence base
• The unique truffle-parasitic ecology (parasitizing Elaphomyces species) distinguishes C. ophioglossoides from all other medicinal Cordyceps species and presents cultivation challenges that limit commercial development